Translational medicine, which bridges the science of the emerging preclinical portfolio and the early development space where molecules are studied in humans for the first time, is an important if not essential element of successful pharmaceutical development.
If you want to understand why Regeneron R&D chief George Yancopolous gets a king's ransom in annual compensation, you need look no further than the Phase IIb data that has just been posted on dupilumab for severe eczema.
Gynesonics has raised an additional $6 million in its march toward raising a total round of $35.5 million in equity and debt, according to an SEC filing. The additional cash is timely, coming on the heels of its receipt of a European CE mark for and treatment of the first patient with its next-generation VizAblate System in June.
Allergan execs have made no secret of the fact that they've been planning to come up with a lean-and-mean game plan designed to prove to investors that they'd be much better off if they spurned Valeant's offer to buy the company and gut its R&D division. Citing sources close to the company, Bloomberg is reporting that the cutbacks should include work on its most "unpromising" programs in the pipeline.
Researchers at the University of Georgia have developed a new formulation of the chemotherapy drug cisplatin that targets mitochondrial DNA, and is delivered via a polymeric nanoparticle 1,000 times smaller than the width of human hair.
The U.S. National Institutes of Health granted Sorrento Therapeutics $2.6 million to develop antibacterial immunotherapies.
The San Francisco-based company is currently developing antibacterial non-antibody proteins against food and animal bacterial pathogens that the company calls Purocin proteins. AvidBiotics president and co-founder Jim Knighton told FierceAnimalHealth that these engineered proteins are "the antithesis of a broad spectrum antibiotic."
A new contraceptive implant developed by Lexington, MA-based MicroCHIPS could give women remote-controlled access to their hormone administration, offering up to 16 years of specifically dosed delivery and thus more authority over their birth control regimens.
AstraZeneca is expanding iMed, its virtual R&D project, through a cardiovascular-focused agreement with Germany's Max Planck Institute of Molecular Physiology that will focus on early-stage research.
Conventional imaging methods don't work so well in the gut, the site of irritable bowel syndrome, celiac disease and Crohn's disease among others. Researchers at the University of Buffalo say they have solved the problem, albeit in animal studies.